ADMP - Adamis Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.23
-0.22 (-6.33%)
As of 1:45PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.45
Open3.45
Bid3.15 x 800
Ask3.20 x 900
Day's Range3.17 - 3.45
52 Week Range2.35 - 5.85
Volume348,707
Avg. Volume447,526
Market Cap107.901M
Beta0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.41
Trade prices are not sourced from all markets
  • Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
    Zacks24 days ago

    Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

    Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock
    Zackslast month

    Options Traders Expect Huge Moves in Adamis Pharmaceuticals (ADMP) Stock

    Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Associated Press2 months ago

    Adamis: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 23 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...

  • GlobeNewswire2 months ago

    Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update

    Adamis Pharmaceuticals Corporation (ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, said, “We have made a substantial amount of progress on several fronts since the beginning of the year.  The development of our product pipeline continues to move forward and we have several target milestones that we hope to reach later this year.  We believe the completion of these milestones will increase shareholder value. Symjepi ™ (epinephrine) Injection 0.15mg – The FDA determined that the company’s NDA for Symjepi ™ (epinephrine) Injection 0.15mg was sufficiently complete to permit a substantive review and indicated that no potential review issues were identified as of the date of the agency’s communication in February.  Approval is expected in the second half of this year.

  • Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

    Investors in Adamis Pharmaceuticals (ADMP) need to pay close attention to the stock based on moves in the options market lately.

  • High Growth Stocks To Invest In
    Simply Wall St.2 months ago

    High Growth Stocks To Invest In

    Robust, high-growth companies such as Adamis Pharmaceuticals are appealing to investors for many reasons. They bring about a strong upside to your portfolio, and less downside risk as opposed toRead More...

  • GlobeNewswire2 months ago

    Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)
    Zacks2 months ago

    What Falling Estimates & Price Mean for Adamis Pharmaceuticals (ADMP)

    Adamis Pharmaceuticals (ADMP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

  • Capital Cube6 months ago

    ETFs with exposure to Adamis Pharmaceuticals Corp. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Adamis Pharmaceuticals Corp. Here are 5 ETFs with the largest exposure to ADMP-US. Comparing the performance and risk of Adamis Pharmaceuticals Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Stocks to Watch: Revance Therapeutics and Adamis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / December 6, 2017 / Shares of Revance headed higher on Tuesday after announcing successful results in a pair of phase 3 clinical trials that are evaluating its RT002 treatment ...

  • SmarterAnalyst7 months ago

    Raymond James Sings the Praises of Adamis Pharmaceuticals; Here’s Why

    What does the future hold for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)? Raymond James analyst Elliot Wilbur is out today with a bullish note on the specialty biopharmaceutical company, after the latter announced that it has submitted an IND to test naloxone in human patients using Symject, presumably as a reaction to the worsening opioid crisis.

  • SmarterAnalyst7 months ago

    Adamis Pharmaceuticals Corp (ADMP) Moves Forward with a New Opioid Overdose Drug

    Adamis Pharmaceuticals Corp (NASDAQ:ADMP) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin testing the drug compound naloxone in human patients.  Adamis intends to develop a naloxone injection product candidate utilizing the same patented SymjectTM syringe drug delivery platform used in Adamis’ approved SymjepiTM product, which is an epinephrine injection drug/device combination for the emergency treatment of acute allergic reactions including anaphylaxis. Naloxone is an opioid antagonist used to treat narcotic overdoses.  Naloxone, which is generally considered the drug of choice for immediate administration for opioid overdose, blocks or reverses the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness.  Common opioids include morphine, heroin, tramadol, oxycodone, hydrocodone and fentanyl.

  • SmarterAnalyst7 months ago

    This Bull Cheers for Adamis Pharmaceuticals Following PAS Submission for Pediatric Version of Epinephrine Auto-Injector Symjepi

    Adamis Pharmaceuticals (NASDAQ:ADMP) investors sent the stock on a nearly 9% gain in value yesterday on back of the news of the company's submission to the FDA of a prior approval supplement (PAS) for the pediatric version of Symjepi. With the pediatric version designed differently than the original, FBR analyst Andrew D'silva actually sees less risk circling a potential approval on ADMP's allergy shot than the original version of the epinephrine auto-injector, a cheaper option to competitor Mylan's EpiPen.